Neutrophil-to-Lymphocyte Ratio – Risk of Amputation and Mortality in Patients with Limb-Threatening Ischemia – a Systematic Review
and | Mar 21, 2024
About this article
Article Category: Review
Published Online: Mar 21, 2024
Page range: 7 - 12
Received: Dec 20, 2023
Accepted: Feb 05, 2024
DOI: https://doi.org/10.2478/jce-2024-0006
Keywords
© 2024 Bogdan Ioan Lăpădatu et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
FIGURE 1.
Disease etiology, treatment, and outcomes of patients with ALI
| Taşoğlu et al. |
9.7 | 6.1 | 5.2 | 0.7 | 63% | 63% | Amputation |
| Coelho et al. |
8.8 | 3.6 | 5.4 | 0.860 | 90.5% | 73.6% | Death or major amputation at 30 days |
| Taurino et al. |
– | – | 5 | 0,823 | – | – | Amputation at 30 days |
| – | – | 5 | 0.776 | – | – | Mortality at 30 days | |
| Pasqui et al. |
8.9 | 6.5 | 6.66 | 0.712 | 77.8% | 65.3% | Amputation at 26.9 ± 22.1 months |
| 8.08 | 5.6 | 5.57 | 0.639 | 62.3% | 56.04% | Mortality at 26.9 ± 22.1 months | |
| Arbănași et al. |
5.78 | 2.61 | 4.23 | 0.829 | 70.2% | 83% | Major amputation at 30 days |
| Spark et al. |
– | – | 5.25 | 0.690 | 69% | 71% | Mortality at 8.7 months (3.1–16 months) |
| Chan et al. |
– | – | 5.25 | – | – | – | Mortality at 12 months |
| Gonzalez-Fajardo et al. |
– | – | 5 | 0.64 | 32% | 87.5% | Amputation-free survival at 31 months |
| Erturk et al. |
– | – | 3 | – | – | – | Cardiovascular death at 20 months (12–27 months) |
| Taşoğlu et al. |
3.8 | 2.4 | 3.2 | 0.71 | – | – | Major amputation at 46 months |
| Su et al. |
– | – | 8 | – | 62% | 82.1% | Mortality at 12 months |
| Russu et al. |
6.40 | 2.21 | 3.95 | 0.821 | 82.6% | 89.9% | Primary patency at 12 months |
Clinical cases and surgical procedures for ALI
| Taşoğlu et al. |
224 (92%) | 21 (8%) | 44 (18%) | 189 (78%) | – | 224 (92%) | 21 (8%) | – | 36 (14.69%) | 25 (10%) |
| Coelho et al. |
157 (45.5%) | 188 (54.5%) | 60 (17.4%) | 261 (75.7%) | 24 (7%) | 280 (81.2%) | 35 (10.1%) | 30 (8.7%) | 84 (24.34%) | – |
| Taurino et al. |
73 (41.3%) | 104 (58.7%) | – | – | – | 95 (53.7%) | 9 (5.1%) | 73 (41.2%) | 23 (12.9%) | 29 (16.4%) |
| Pasqui et al. |
67 (39.9%) | 121 (60.1%) | 19 (11.3%) | 138 (82.1%) | 11 (6.5%) | – | – | – | 18 (10.7%) | 77 (45.8%) |
| Arbănași et al. |
– | – | – | – | – | 118 (72.39%) | 38 (23.31%) | 7 (4.29%) | 57 (27.14%) | 47 (22.38%) |
The general characteristics of the studies included in the review
| Taşoğlu et al. |
2013 | Turkey | 245 | 66.04 | 152 (62%) | 144 (59%) | – | 60 (24%) | 170 (70%) |
| Coelho et al. |
2021 | Portugal | 345 | 73 | 188 (54.5%) | 277 (83.5%) | 157 (45.5%) | 92 (27.5%) | 136 (39.4%) |
| Taurino et al. |
2021 | Italy | 177 | 78.9 | 115 (65%) | 145 (81.9%) | – | 70 (39.5%) | – |
| Pasqui et al. |
2021 | Italy | 168 | 77.8 | 109 (64.9%) | 128 (76.1%) | 45 (26.7%) | 54 (32.1%) | 18 (10.7%) |
| Arbănași et al. |
2022 | Romania | 210 | 69.56 | 153 (72.86%) | 175 (83.33%) | 169 (80.48%) | 111 (52.86%) | 134 (63.81%) |
| Spark et al. |
2010 | UK | 149 | 72 | – | 83 (55.7%) | – | 44 (29.53%) | 103 (69.12%) |
| Chan et al. |
2014 | Australia | 97 | 81 | 50 (64.9%) | 42 (54.6%) | 49 (63.6%) | 46 (59.7%) | – |
| Gonzalez-Fajardo et al. |
2014 | Spain | 561 | 74 | 465 (83%) | 354 (63.10%) | 131 (23.35%) | 258 (45.98%) | 362 (64.52%) |
| Erturk et al. |
2014 | Turkey | 508 | 64 | 413 (81.3%) | 311 (61.22%) | 207 (40.74%) | 213 (41.92%) | 266 (52.36%) |
| Taşoğlu et al. |
2014 | Turkey | 104 | 69 | 86 (82.7%) | 46 (44.2%) | – | 39 (37.5%) | 74 (71.2%) |
| Su et al. |
2021 | Taiwan | 195 | 74 | 102 (52.3%) | 129 (66.15%) | 75 (38.46%) | 134 (68.71%) | 46 (23.58%) |
| Russu et al. |
2022 | Romania | 224 | 69.72 | 166 (74.11%) | 186 (83.04%) | 181 (80.8%) | 110 (49.11%) | 141 (62.95%) |